<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="plants fungi food supplements cardiovascular diseases neurodegenerative diseases Alzheimerâ€™s disease" exact="metabolic syndrome" post="1. Introduction Fungi and plants represent an important source"/>
 <result pre="be dangerous. Taxanes, used for the treatment of patients with" exact="breast cancer," post="are an excellent example of a valuable drug: paclitaxel"/>
 <result pre="carbonic anhydrase and cholinesterase inhibitory activity, with potential uses against" exact="epilepsy" post="and Alzheimerâ€™s disease, respectively. Moreover, nine flavonoids were isolated"/>
 <result pre="treatment of AD. During a recent study conducted on murine" exact="neuroblastoma" post="Neuro2A cells, lichen-derived secondary metabolites (atranorin, perlatolic acid, physodic"/>
 <result pre="their influence on Î±SN aggregates. The treatment of KCl-depolarized SH-SY5Y" exact="neuroblastoma" post="cells with GA and AA led to a progressive"/>
 <result pre="GA, still showed potential to improve cognitive function in mild" exact="dementia" post="patients after &amp;gt;24 weeks administration at a dosage of"/>
 <result pre="comprises a variety of pathological states, ranging from type 2" exact="diabetes mellitus" post="(T2DM) to obesity, hyperlipidemia and hypertension [55]. Obesity and"/>
 <result pre="all underlying pathological conditions is required for the therapy of" exact="metabolic syndrome." post="Although the first step in such a therapeutic regime"/>
 <result pre="is necessary [59]. Over the years, the different aspects of" exact="metabolic syndrome" post="have been thoroughly studied, and a number of potential"/>
 <result pre="associated with the development of other disorders such as T2DM," exact="cardiovascular disease" post="and nonalcoholic fatty liver disease. Behavioral interventions, including dietary"/>
 <result pre="of other disorders such as T2DM, cardiovascular disease and nonalcoholic" exact="fatty liver disease." post="Behavioral interventions, including dietary changes and increased physical exercise,"/>
 <result pre="other disorders such as T2DM, cardiovascular disease and nonalcoholic fatty" exact="liver disease." post="Behavioral interventions, including dietary changes and increased physical exercise,"/>
 <result pre="dietary changes and increased physical exercise, are important to prevent" exact="obesity" post="and to induce weight loss, however pharmacological treatment is"/>
 <result pre="A viable strategy for the treatment of metabolic disorders like" exact="obesity" post="is decreasing the absorption of dietary components such as"/>
 <result pre="stimulation of energy expenditure. Defects in leptin production cause severe" exact="obesity" post="[98]. A growing body of literature demonstrates the potential"/>
 <result pre="and weight loss, a promising profile for the treatment of" exact="obesity" post="[88]. 3.3. Hypertension and Hyperinflammation-Managing Cardiovascular Risk in Metabolic"/>
 <result pre="another important component of MS which, along with hypercholesterolemia, cause" exact="atherosclerosis" post="and therefore significantly raise the cardiovascular risk linked to"/>
 <result pre="promising way to prevent cardiovascular risk related to hyperinflammation and" exact="atherosclerosis" post="is to target the macrophages that accumulate in the"/>
 <result pre="have vasodilative effects, potentially useful in alleviating hypertension linked to" exact="atherosclerosis" post="[74]. Finally, three new alkaloids (communesin I, fumoquinazoline Q"/>
 <result pre="related disordersNeurosci. Biobehav. Rev.20167186587710.1016/j.neubiorev.2016.10.02327826066 7.ShahidiF.YeoJ.D.Bioactivities of phenolics by focusing on" exact="suppression" post="of chronic diseases: A reviewInt. J. Mol. Sci.201819157310.3390/ijms19061573 8.HuangX.-T.LiX.XieM.-L.HuangZ.HuangY.-X.WuG.-X.PengZ.-R.SunY.-N.MingQ.-L.LiuY.-X.et"/>
 <result pre="PatientsFront Pharmacol.201910168810.3389/fphar.2019.0168832153388 55.EckelR.H.GrundyS.M.ZimmetP.Z.The metabolic syndromeLancet20053651415142810.1016/S0140-6736(05)66378-715836891 56.RitchieS.A.ConnellJ.M.C.The link between abdominal obesity," exact="metabolic syndrome" post="and cardiovascular diseaseNutr. Metab. Cardiovasc. Dis.20071731932610.1016/j.numecd.2006.07.00517110092 57.Luna-VÃ¡zquezF.J.Ibarra-AlvaradoC.Rojas-MolinaA.Rojas-MolinaI.Zavala-SÃ¡nchezM.Ã�.Vasodilator compounds derived"/>
 <result pre="in the Therapy of AtherosclerosisOxid. Med. Cell. Longev.2020202011210.1155/2020/1232816 88.LiuJ.LeeJ.HernandezM.A.S.MazitschekR.OzcanU.Treatment of" exact="obesity" post="with celastrolCell2015161999101110.1016/j.cell.2015.05.01126000480 89.OlokobaA.B.ObateruO.A.OlokobaL.B.Type 2 diabetes mellitus: A review of"/>
 <result pre="2 Natural compounds with potential use in the therapy of" exact="metabolic syndrome" post="and/or with additional effects for the reduction of cardiovascular"/>
</results>
